A Phase I Clinical Study of GC012F Injection in Subjects with Relapsed/Refractory Multiple Myeloma
| Title | A Phase I Clinical Study of GC012F Injection in Subjects with Relapsed/Refractory Multiple Myeloma |
|---|---|
| Description | This is a single-arm, non-randomized, open-label study to evaluate the safety and efficacy of GC012F injection in patients with Relapsed/Refractory multiple myeloma (RRMM).Approximately 6-9 eligible patients will be enrolled in 3 dose cohorts to evaluate the safety of GC012F injection. |
| Organism | Homo sapiens |
| Data Type | Protein Biomarkers |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA023223 |
| Release Date | 2024-01-30 |
| Submitter | mingyue xiang (mingyue.xiang@gracellbio.com) |
| Organization | Gracell Biotechnologies Inc |
| Submission Date | 2024-01-26 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX005754-03 | RRMM-INDlike(2) | 1 | Protein Biomarkers | 22.1 KB | xlsx | 0 | Controlled |